
Addiction Medication Before Surgery Rose 81% in Medicaid. Trauma Patients Still Get It Least.
The two papers were published on Nov. 20 in different journals, by researchers who never cite each other, using datasets that share nothing but a diagnosis code. Read together they describe the same hole in American hospital care from opposite ends: what happens to a person with opioid use disorder in the weeks before an operation, and what happens to that person once the operation puts them in a bed.
The first is national. A team at the University of Michigan, led by anesthesiologist Mark Bicket, pulled the Transformed Medicaid Statistical Information System files for every surgical procedure billed to Medicaid between July 2016 and the end of 2021 — 13,115,728 procedures performed on 7,967,328 beneficiaries aged 12 to 64, all of whom had been continuously enrolled for at least 180 days before their operation. They then asked a narrow question of that enormous file: did the patient have a claim for buprenorphine, methadone, or naltrexone in the six months before going to the operating room.
The answer, published in JAMA Health Forum, is that the share rose substantially and remained small.
What the numbers moved from, and to
| Measure (per 100,000 surgical procedures) | 2016 | 2021 |
|---|---|---|
| Any MOUD, unadjusted | 1,440.0 | 2,278.3 |
| Any MOUD, adjusted | 185.8 | 337.1 |
| Buprenorphine | 808.8 | 1,453.5 |
| Methadone | 589.6 | 756.5 |
| Naltrexone | 69.9 | 129.2 |
The crude prevalence of preoperative addiction medication rose 58 percent. Adjusted for demographics, insurance and clinical factors, it rose 81 percent. In the final year of the study, roughly one in 44 Medicaid surgical procedures carried an addiction-medication claim in the preceding six months. The authors say their sensitivity analyses — dropping states and years with weaker data reporting — produced similar estimates, which matters, because Medicaid claims data quality varies enough by state that an unexamined trend in reporting could manufacture a trend in treatment.
Three details are worth sitting with. The cohort was 65.2 percent female and had a mean age of 40.7, which is what a Medicaid surgical population looks like once obstetric and gynecologic procedures are counted. The highest prevalence the authors report is not in a general surgery category at all: it is tricuspid or mitral valve repair, at 11,393.8 per 100,000 procedures.
And the growth was not evenly distributed across the three medications.
Buprenorphine nearly doubled. Methadone didn't.
Buprenorphine went from 808.8 to 1,453.5 per 100,000, a 79.7 percent increase, and supplied most of the total rise. Extended-release naltrexone grew faster in relative terms, 84.9 percent, from a much smaller base. Methadone, the oldest and most heavily regulated of the three, grew 28.3 percent.
That ordering tracks prescribing friction more closely than it tracks clinical need. Since the federal X-waiver requirement was eliminated, buprenorphine can be started by any clinician with a standard DEA registration, and a patient can carry a month of it in a bag. Methadone for opioid use disorder can only be dispensed by a certified opioid treatment program under 42 CFR Part 8, which means daily attendance at a specific building, take-home doses governed by federal and state rules, and — for anyone facing surgery — a coordination problem between an OTP that closes at noon and a hospital that wants the patient NPO from midnight.
The paper does not perform that comparison. It does not need to for the pattern to be legible: the medication that doubled is the one a surgeon's office can prescribe, and the medication that barely moved is the one that requires a second institution to stay involved. For a patient whose treatment is stable on medication-assisted treatment, the practical consequence is that the perioperative handoff is far more fragile on methadone than on buprenorphine, and the national trend is quietly shifting toward the easier drug.
The operation with the highest rate is the one the disorder causes
Tricuspid and mitral valve repair sits at 11,393.8 per 100,000 procedures — 11.4 percent, about five times the crude average across all surgery. The study offers no explanation, and the most plausible one is unglamorous: in a population aged 12 to 64 on Medicaid, valve repair is disproportionately the surgical treatment of infective endocarditis, and right-sided endocarditis in the United States is overwhelmingly a complication of injection drug use.
If that reading holds, the finding inverts the usual framing of this literature. The surgical service where addiction medication is most common is not a service that has solved perioperative addiction care. It is the service that treats the damage the untreated disorder has already done, on patients who arrive with a known diagnosis, an active infection, and a medication list that someone has already had to reconcile.
At one hospital, one in five got medication — and trauma came last
The second study is small and local, and it answers the question the national claims file cannot: once the patient is inside, does anyone act on the diagnosis.
Researchers at Washington University in St. Louis reviewed 5,919 hospital encounters at their tertiary academic medical center between July 2018 and June 2024, including any patient with an opioid-related diagnosis code or a fentanyl-positive urine drug screen during the encounter or in the six months before it. Just 1,228 of those encounters — 20.7 percent — involved MOUD treatment.
The variation by service line is the finding. Compared with patients discharged from the general medicine service, those discharged from obstetrics and gynecology had roughly double the odds of receiving MOUD (adjusted odds ratio 2.07, 95% CI 1.65–2.60). Patients discharged from psychiatry had 63 percent lower odds (aOR 0.37, 0.28–0.48). Patients discharged from trauma surgery had 86 percent lower odds (aOR 0.14, 0.11–0.18) — the lowest of any service the authors examined.
Two other associations cut against any comfortable story about who gets treated. White race and Medicaid insurance both predicted MOUD receipt, in a cohort that was 50.9 percent non-white. And addiction medicine consultation was by far the strongest correlate in the model, at an adjusted odds ratio of 4.43 (3.64–5.40).
Reading the 4.43
That last number should be read with care rather than enthusiasm. A consultation is not assigned at random; it is requested when a clinician recognizes the disorder and decides to escalate, so the odds ratio blends the effect of the consultation with the effect of the recognition that produced it. What the study can support is narrower and still useful: at this hospital, the presence of a specialist team is the single factor most tightly bound to whether a patient with opioid use disorder left on medication, and the service lines that treat the most injured patients were the least likely to get that team involved.
What a patient can ask before the operation
The two papers do not test any intervention, so nothing here is a protocol. But they identify the points where the handoff fails, and those points have questions attached to them.
Ask whether buprenorphine, methadone or naltrexone will be continued through the day of surgery rather than held because of a blanket "nothing by mouth" rule, and ask who is authorized to prescribe it in the hospital. Ask for an addiction medicine consult by name, since the St. Louis data suggest that is the difference between 20 percent and something better. Patients on methadone should ask the surgical team which OTP dose will be given on the day of discharge and who arranges transport to the program afterward — the federal rule that governs methadone dispensing does not pause for a hospital stay. And ask for naloxone at discharge along with a written plan, because the days after an operation combine reduced tolerance, resumed use and a prescription bottle in the house.
The national trend is in the right direction. It is also, at 337 adjusted procedures per 100,000 in the last year of the data, still describing a minority of patients with the diagnosis, in a system where the median surgical patient with opioid use disorder may never speak to a specialist.
Where the evidence stops
Neither study measures whether anyone lived. The JAMA analysis ends in 2021, before the most recent shifts in the illicit fentanyl supply, and its outcome is a claim within 180 days — a measure of recent exposure, not of medication in the bloodstream on the morning of surgery. The St. Louis cohort is one hospital, and its inclusion criteria depend on a diagnosis code or a urine screen, which means patients whose disorder was never documented are invisible in exactly the places where documentation is weakest. Both are observational. Neither can say whether the rise in preoperative prescribing reflects better care, better coding, or a sicker surgical population.
What they can say is that the medication exists, that it works, and that whether a patient gets it around an operation still depends on which service happens to admit them.
Sources
- Bicket MC, Chua KP, Lagisetty P, et al. Trends in Medications for Opioid Use Disorder Before Surgery Among Medicaid Beneficiaries. JAMA Health Forum. 2026;7(11):e264407
- PubMed record 43062818 — JAMA Health Forum study abstract
- Hoemann BL, Lane A, Laine R, et al. Association of Medications for Opioid Use Disorder Use With Addiction Medicine Consultation and Hospital Service Line. Substance Use & Addiction Journal, published online Nov. 20, 2026
Editorial Board
LADC, LCPC, CASAC
The Rainier Rehab editorial team consists of licensed addiction counselors, healthcare journalists, and recovery advocates dedicated to providing accurate, evidence-based information about substance abuse treatment and rehabilitation.
Related Articles

Pennsylvania Halved Its Overdose Deaths. Its Hospitals Just Broke a Record.
State discharge data show 37,287 opioid-related hospitalizations in 2025, the most in seven years, while overdose deaths fell to 2,810. A veterinary sedative explains part of the gap.

The 1930s Map Still Sorts Who Dies of an Overdose in Massachusetts
A new study links federal redlining grades to opioid overdose deaths across Massachusetts census tracts, with a death rate 86 percent higher in the tracts graded Hazardous than in those graded Best.

The Cord Tissue Knew the Dose. It Didn't Know the Withdrawal.
A 94-newborn cohort found umbilical cord methadone tracked maternal dose closely but predicted nothing about withdrawal severity, undercutting dose reduction.